Hipolabor would support regulatory activities, supply, distribution and commercialization. The companies would share development costs equally and operate a 50–50 profit-sharing model. Hipolabor could also receive sales milestones linked to the first USD 200 million in cumulative net sales.

The agreement is expected to be finalized in the coming months. SynAct would retain control of resomelagon and remain free to pursue partnerships in other territories and indications.

“We are impressed with [Hipolabor’s] ability to scale their business to success,” said Jeppe Øvlesen, CEO of SynAct Pharma.

The Brazilian programme builds on SynAct’s RESOVIR-2 development programme. Resomelagon remains investigational and is not approved for treating dengue.